Male | Female | Total | |||||
Count | Rate per 100 000 doses (90% CI) | Count | Rate per 100 000 doses (90% CI) | Count | Rate per 100 000 doses (90% CI) | ||
Total | 62 | 13.6 (10.9 to 16.8) | 13 | 2.9 (1.7 to 4.7) | 75 | 8.3 (6.8 to 10.1) | |
Age group (years) | 12–15 | 34 | 11.4 (8.4 to 15.2) | 7 | 2.4 (1.1 to 4.6) | 41 | 7.0 (5.3 to 9.1) |
16–17 | 28 | 17.7 (12.6 to 24.2) | 6 | 3.9 (1.7 to 7.6) | 34 | 10.8 (8.0 to 14.4) | |
Dose | 1 | 10 | 4.4 (2.4 to 7.5) | 4 | 1.8 (0.6 to 4.2) | 14 | 3.2 (1.9 to 4.9) |
2 | 52 | 24.2 (19.0 to 30.5) | 9 | 4.3 (2.3 to 7.5) | 61 | 14.4 (11.5 to 17.8) | |
Brighton collaboration level | Definitive | 27 | 5.9 (4.2 to 8.2) | 3 | 0.7 (0.2 to 1.8) | 30 | 3.3 (2.4 to 4.5) |
Probable | 35 | 7.7 (5.7 to 10.2) | 10 | 2.3 (1.2 to 3.8) | 45 | 5.0 (3.8 to 6.4) |